EcoDrugPlus

Adrenergic Receptor, Alpha 1d

Ensembl ID : ENSMSIG00000020251
Gene Symbol: ADRA1D
1 Cross references
209 Possible Orthologues:

Adrenergic Receptor, Alpha 2a

Ensembl ID : ENSMSIG00000031292
Gene Symbol: ADRA2A
1 Cross references
245 Possible Orthologues:

Adrenergic Receptor, Alpha 2b

Ensembl ID : ENSMSIG00000019270
Gene Symbol: ADRA2B
1 Cross references
234 Possible Orthologues:

Adrenergic Receptor, Alpha 2c

Ensembl ID : ENSMSIG00000023019
Gene Symbol: ADRA2C
1 Cross references
242 Possible Orthologues:

Adrenergic Receptor, Beta 1

Ensembl ID : ENSMSIG00000031171
Gene Symbol: ADRB1
1 Cross references
176 Possible Orthologues:

Adrenergic Receptor, Beta 2

Ensembl ID : ENSMSIG00000005196
Gene Symbol: ADRB2
1 Cross references
278 Possible Orthologues:

Adrenergic Receptor, Beta 3

Ensembl ID : ENSMSIG00000030070
Gene Symbol: ADRB3
1 Cross references
230 Possible Orthologues:

Advanced Glycosylation End Product-Specific Receptor

Ensembl ID : ENSMSIG00000007661
Gene Symbol: AGER
1 Cross references
184 Possible Orthologues:

Amine Oxidase Copper Containing 1-Like 2

Ensembl ID : ENSMSIG00000020742
Gene Symbol: AOC1L2
1 Cross references
217 Possible Orthologues:

Amine Oxidase Copper Containing 1-Like 3

Ensembl ID : ENSMSIG00000020665
Gene Symbol: AOC1L3
1 Cross references
217 Possible Orthologues:

Amine Oxidase, Copper Containing 3

Ensembl ID : ENSMSIG00000006909
Gene Symbol: AOC3
1 Cross references
336 Possible Orthologues:

Amine Oxidase, Copper-Containing 1

Ensembl ID : ENSMSIG00000020753
Gene Symbol: AOC1
1 Cross references
218 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).